.Attribute Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin caused strengthened progression-free as well as general survival, bring about FDA approval and a new treatment choice for patients.